Aileron Therapeutics Announces FDA Acceptance of IND for ALRN-6924 as a Myelopreservation Agent in Patients with p53-mutant Cancer ...
WATERTOWN, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that the U.S. Food and Drug …